A Single-Arm, Prospective, Phase II Study of Cisplatin Plus Weekly Docetaxel as First-Line Therapy in Patients with Metastatic or Recurrent Salivary Gland Cancer

PURPOSE: Salivary gland cancers (SGCs) are relatively rare but comprise various histologic subtypes, which complicates design of prospective trials. Systemic chemotherapy plays a limited role in treatment of SGCs, but cisplatin and docetaxel showed efficacy in a previous preclinical study. Here, we...

Descripción completa

Detalles Bibliográficos
Autores principales: Kim, Hye Ryeon, Lee, Su Jin, Park, Sehhoon, Jung, Hyun Ae, Lee, Se-Hoon, Jeong, Han-Sin, Chung, Man Ki, Ahn, Myung-Ju
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Korean Cancer Association 2022
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9296942/
https://www.ncbi.nlm.nih.gov/pubmed/34727492
http://dx.doi.org/10.4143/crt.2021.1019

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9296942/
https://www.ncbi.nlm.nih.gov/pubmed/34727492
http://dx.doi.org/10.4143/crt.2021.1019

Ejemplares similares